

**Supplement Table 2: Mean Simulated Outcomes by Hepatitis C Antibody Screening Strategy**

Outcome	No Screening	Current Risk based Screening	Birth Cohort Screening with Drug Therapy	
			Two	Three
Antibodies	2,411,506	2,411,506	2,411,506	2,411,506
Chronic infections	1,920,760	1,920,760	1,920,760	1,920,760
Persons aware of their infection prior to 2006	674,480	674,480	674,480	674,480
Ever developed compensated cirrhosis	1,039,141	994,291	855,850	791,053
Ever developed decompensated cirrhosis	376,662	360,388	310,184	286,699
Ever developed hepatocellular carcinoma	241,200	230,784	198,627	183,595
Ever received a transplant	79,171	75,752	65,204	60,268
Antibody screening tests administered	0	14,793,816	60,404,514	60,404,514
Positive results delivered to patient	0	262,260	1,070,840	1,070,840
Patients contraindicated for treatment for modifiable reasons	0	44,644	182,261	182,261
Patients contraindicated for treatment for non-modifiable reasons	0	22,289	90,994	90,994
Patients refusing treatment	0	18,721	76,268	76,268
Patients treated	0	135,089	551,800	551,800
Patients who achieved a sustained viral response	0	53,160	229,515	310,855
Deaths from hepatitis C virus	617,863	591,172	508,812	470,293
Total medical Costs	\$14,690,474,383	\$16,462,349,842	\$21,926,085,340	\$35,449,453,803
Non-antiviral hepatitis C virus medical management costs	\$14,690,474,383	\$14,200,143,284	\$12,686,980,451	\$11,709,726,977
Screening costs	0	\$753,897,535	\$3,077,532,475	\$3,077,532,382
Antiviral costs	0	\$1,508,309,022	\$6,161,572,414	\$20,662,194,443
Productivity losses	\$3,303,709,698	\$5,540,773,993	\$12,440,840,318	\$12,240,299,713

---

Total costs (medical and productivity)	\$17,994,184,081	\$22,003,123,835	\$34,366,925,658	\$47,689,753,515
Quality-adjusted life years (QALY) experienced	1,094,782,026	1,094,895,076	1,095,243,882	1,095,427,317

---

Note: All costs and QALYs discounted to 2010 values using a 3% annual rate.